Taysha Gene Therapies Inc

TSHA remains in medium-term distribution with active lower highs and lower lows under declining EMAs, trading near extreme oversold levels at the 200-day SMA. The medium-term bias is bearish, but short-term exhaustion and oversold RSI suggest caution on new shorts. Execution is best deferred into rallies toward the 9/20 EMA zone for rejection. The long-term uptrend stays intact above the rising 200-day SMA. Key risks include a relief bounce reclaiming the 20 EMA or a breakdown below the 200-day SMA invalidating core structural signals.

• ↑Breakthrough therapy designation and 100% early trial response rate accelerate BLA path.
• ↑Catalent manufacturing agreement ensures scalable supply for anticipated 2027 launch.
• ↓Net loss of $109M and $86.4M R&D spend in 2025 strain finances.